查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2089095

抗癌藥物市場：2026-2032年全球市場預測（按藥物類別、分子類型、給藥途徑、治療階段、患者年齡層、適應症、分銷管道和最終用戶分類）

Anti-Tumor Drugs Market by Drug Class, Molecule Type, Route Of Administration, Therapy Line, Patient Age Group, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗癌藥物市場將成長至 3,056.3 億美元，年複合成長率為 10.50%。

主要市場統計數據
基準年 2025 1518.5億美元
預計年份：2026年 1673.9億美元
預測年份：2032年 3056.3億美元
複合年成長率 (%) 10.50%

癌症仍然是全球最嚴重的健康和經濟負擔之一。根據國際癌症研究機構（IARC）統計，2022年全球新增癌症病例約2,000萬例，癌症相關死亡病例約970萬例。因此，抗癌藥物市場需求龐大且迫切，涵蓋細胞毒性化學療法、標靶治療、免疫腫瘤學、荷爾蒙療法、抗體藥物偶聯物（ADC）、放射性藥物和細胞療法等。

市場發展勢頭受早期診斷、生物標記研發、癌症臨床試驗活動不斷擴展以及精準醫療的普及所驅動。隨著實證醫學報銷機制日益重要，產業領導者正優先考慮那些能夠顯著提高生存率、持續緩解、毒性可控且具有明確衛生經濟價值的療法。

癌症治療格局的變革性變化

抗癌藥物領域正從針對廣泛腫瘤部位的治療模式轉向分子層面的精準治療。伴隨診斷、新一代定序、微量殘存疾病（MRD）檢測和液態生物檢體技術能夠更精準地篩選患者，而標靶治療和免疫療法則持續改變肺癌、乳癌、骨髓惡性腫瘤、黑色素瘤和消化器官系統惡性腫瘤的標準治療方案。

人工智慧對抗癌藥物的累積影響

人工智慧（AI）正成為抗癌藥物發現、臨床開發、藥物安全監測和商業化各階段的實質驅動力。人工智慧平台正被用於標靶識別、蛋白質-蛋白質相互作用建模、臨床實驗室方案最佳化、化合物篩檢、患者分層以及從複雜資料集中檢測安全訊號。包括美國食品藥物管理局（FDA）在內的監管機構報告稱，人工智慧和機器學習在藥物和生技藥品核准申請中的應用日益廣泛。

全球腫瘤市場關鍵區域洞察

由於亞太地區人口眾多、癌症診斷數量不斷增加且發病率持續上升，該地區已成為癌症治療的重點區域。根據 GLOBOCAN 2022 的數據，亞洲佔全球新增癌症病例的近一半，癌症死亡病例的一半以上。中國、日本、印度、韓國和澳洲在癌症臨床研究、監管現代化、生物相似藥應用和擴大醫療服務可及性方面發揮著核心作用，但各國在保險覆蓋範圍和生物標記檢測的可及性方面存在顯著差異。

針對不同族群在癌症治療取得和發展的關鍵見解。

東協擁有巨大的長期發展潛力，印尼、越南、泰國、馬來西亞、新加坡和菲律賓的癌症醫療服務正在擴大。然而，抗癌藥物的取得仍然分散，公共保險、私人保險和醫院採購等因素都發揮作用。新加坡是該地區臨床和監管的標桿，而更大的東協市場則蘊藏著巨大的商機，其市場規模涵蓋了價格合理的癌症治療、生物相似藥、伴隨診斷以及能力建設夥伴關係等領域。

各國抗癌藥物商業化情形的關鍵訊息

美國是抗癌藥物最具影響力的市場，這得益於FDA的批准、NCI資助的研究、綜合生物標記的應用、高昂的癌症治療費用以及廣泛的臨床試驗活動。加拿大則以高標準的臨床水準和複雜的省級醫保報銷系統為特徵。同時，墨西哥和巴西是拉丁美洲的重要市場，私人通路、公共藥品目錄、生物相似藥的普及以及全國性的癌症治療體系推動了市場需求。

為行業領導者提供的實用建議

產業領導者應優先考慮以生物標記主導的研發、差異化的臨床終點，並在資產規劃早期階段為支付者準備好證據。腫瘤產品組合必須圍繞以下幾點建構：與標準療法的明確定位、聯合治療的潛力、安全性管理、持續療效、對生活品質的影響，以及在各種報銷方案下展現可信的價值。

調查方法

本執行摘要採用結構化的二手研究途徑編寫。研究資料包括國際癌症研究機構（IARC）、世界衛生組織（WHO）、美國食品藥物管理局（FDA）、歐洲藥品管理局（EMA）、國家癌症相關機構、同行評審的腫瘤學文獻、臨床實驗室登記處和經認可的衛生技術評估機構的公開數據。

結論

抗癌藥物市場正進入一個以精準醫療、免疫療法聯合治療、人工智慧驅動的研發、生物標記整合以及醫保支付方加強監管為特徵的新階段。全球需求受到高癌症發生率、早期診斷、人口老化、臨床研究的拓展以及癌症治療可近性的提高等因素的支持。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：抗癌藥物市場：依藥物類別分類

  • 化療
  • 荷爾蒙療法
  • 免疫療法
  • 標靶治療

第8章：抗癌藥物市場：依分子類型分類

  • 單株抗體
  • 核酸
  • 胜肽
  • 低分子

第9章：抗癌藥物市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下
  • 外用

第10章：抗癌藥物市場：依治療階段分類

  • 一線治療
  • 二線治療

第11章：抗癌藥物市場：依病患年齡層別分類

  • 成人
  • 老年人
  • 兒童

第12章：抗癌藥物市場：依適應症分類

  • 乳癌
  • 結腸癌
  • 肺癌
  • 攝護腺癌

第13章：抗癌藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章：抗癌藥物市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 居家醫療
  • 醫院

第15章：抗癌藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章：抗癌藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章：抗癌藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cybrexa Therapeutics
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Getwell Oncology
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer Inc.
  • Pharma Mar, SA
  • Sanofi SA
  • Taiho Oncology, Inc
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-710B1F0AC60D

The Anti-Tumor Drugs Market is projected to grow by USD 305.63 billion at a CAGR of 10.50% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 151.85 billion
Estimated Year [2026] USD 167.39 billion
Forecast Year [2032] USD 305.63 billion
CAGR (%) 10.50%

Cancer remains one of the world's most consequential health and economic burdens, with the International Agency for Research on Cancer reporting approximately 20 million new cancer cases and 9.7 million cancer deaths in 2022. The anti-tumor drugs market is therefore anchored in a large, medically urgent demand base spanning cytotoxic chemotherapy, targeted therapies, immuno-oncology, hormone therapies, antibody-drug conjugates, radiopharmaceuticals, and cell-based treatments.

Commercial momentum is being shaped by earlier diagnosis, biomarker-driven prescribing, expanding oncology trial activity, and broader adoption of precision medicine. Industry leaders are prioritizing therapies that can demonstrate meaningful survival benefits, durable response, manageable toxicity, and clear health-economic value in increasingly evidence-driven reimbursement environments.

Transformative Shifts in the Oncology Treatment Landscape

The anti-tumor drugs landscape is shifting from broad tumor-site treatment models toward molecularly defined care. Companion diagnostics, next-generation sequencing, minimal residual disease testing, and liquid biopsy are enabling more precise patient selection, while targeted therapy and immunotherapy continue to alter standards of care across lung cancer, breast cancer, hematologic malignancies, melanoma, and gastrointestinal tumors.

At the same time, pricing scrutiny, patent expirations, biosimilar competition, and value-based access models are reshaping commercial strategy. Oncology companies are increasingly pairing clinical differentiation with evidence packages that include overall survival, progression-free survival, patient-reported outcomes, real-world evidence, and payer-relevant cost offsets.

Cumulative Impact of Artificial Intelligence on Anti-Tumor Drugs

Artificial intelligence is becoming a practical enabler across anti-tumor drug discovery, clinical development, pharmacovigilance, and commercialization. AI-enabled platforms are used to identify targets, model protein interactions, optimize trial protocols, screen compounds, stratify patients, and detect safety signals from complex datasets. Regulatory agencies, including the U.S. FDA, have documented growing use of AI and machine learning in drug and biological product submissions.

The cumulative impact is not a replacement for clinical validation but an acceleration of evidence generation. Companies that combine AI with high-quality genomic, imaging, pathology, claims, and real-world datasets are positioned to reduce development friction, improve trial enrollment, and refine market access strategies for precision oncology.

Key Regional Insights Across Global Oncology Markets

Asia-Pacific is a high-priority oncology region due to population scale, expanding diagnosis, and rising cancer incidence; GLOBOCAN 2022 data show Asia accounts for nearly half of global new cancer cases and more than half of cancer deaths. China, Japan, India, South Korea, and Australia are central to oncology clinical research, regulatory modernization, biosimilar adoption, and access expansion, although reimbursement depth and biomarker testing availability vary widely.

North America remains a leading innovation and commercialization hub, supported by FDA pathways, strong biomedical research infrastructure, academic cancer centers, and high adoption of immuno-oncology and targeted therapies. Europe combines advanced oncology infrastructure with increasingly coordinated health technology assessment, including the EU Joint Clinical Assessment framework for oncology medicines beginning in 2025, which is expected to reinforce evidence consistency across member states.

Latin America is advancing through public oncology programs and private-sector growth, with Brazil and Mexico anchoring demand while facing access delays, diagnostic gaps, and budget constraints. The Middle East is investing in specialty care and oncology infrastructure, particularly in Gulf markets with national cancer strategies and advanced hospital networks, while Africa faces the steepest access barriers related to pathology capacity, affordability, medicine availability, and late-stage diagnosis despite a rising cancer burden.

Key Group Insights for Oncology Access and Growth

ASEAN offers strong long-term potential as Indonesia, Vietnam, Thailand, Malaysia, Singapore, and the Philippines expand oncology services, yet anti-tumor drug access remains fragmented across public reimbursement, private insurance, and hospital procurement. Singapore is a regional clinical and regulatory reference point, while larger ASEAN markets represent scale-driven opportunities for affordable oncology medicines, biosimilars, companion diagnostics, and capacity-building partnerships.

The GCC is building advanced cancer care capacity through national health strategies, specialty hospitals, and genomic medicine initiatives, creating demand for innovative oncology drugs and diagnostics partnerships. The European Union is emphasizing evidence harmonization, equitable access, centralized regulatory review, and joint clinical assessment, while BRICS economies are shaping global oncology volume through large patient populations, generic and biosimilar production, clinical trial growth, and expanding local innovation capabilities.

G7 countries remain central to high-value oncology R&D, premium reimbursement, academic research, and early adoption of novel mechanisms, including immunotherapies, antibody-drug conjugates, radioligand therapies, and cell therapies. NATO member markets are not a healthcare bloc, but many allied countries are reinforcing pharmaceutical supply resilience, medicine stockpiling, and secure manufacturing networks that can influence procurement strategies for critical oncology medicines.

Key Country Insights for Anti-Tumor Drug Commercialization

The United States is the most influential anti-tumor drugs market due to FDA approvals, National Cancer Institute-backed research, comprehensive biomarker adoption, high oncology spending, and extensive clinical trial activity. Canada combines strong clinical standards with provincial reimbursement complexity, while Mexico and Brazil are critical Latin American markets where private access, public formularies, biosimilar uptake, and national cancer care capacity shape demand.

In Europe, the United Kingdom, Germany, France, Italy, and Spain represent advanced reimbursement environments with growing emphasis on health technology assessment, budget impact, clinical added benefit, and real-world outcomes. Germany's AMNOG process, the U.K.'s NICE evaluations, and France's HAS assessments materially affect launch sequencing and pricing strategy. Russia remains a large oncology market with localization, procurement, and supply continuity considerations.

China is rapidly expanding domestic oncology innovation, clinical trials, regulatory review capacity, and national reimbursement coverage. India offers scale, cost-efficient pharmaceutical manufacturing, and rising oncology diagnosis but faces affordability constraints and uneven access to advanced diagnostics. Japan and South Korea are mature innovation-led markets with strong regulatory systems, aging populations, and advanced cancer care networks, while Australia supports early access programs and evidence-based reimbursement for high-value cancer therapies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-led development, differentiated clinical endpoints, and payer-ready evidence from the earliest stages of asset planning. Oncology portfolios must be built around clear positioning versus standard of care, combination potential, safety management, durable response, quality-of-life impact, and credible value demonstration across diverse reimbursement systems.

Companies should strengthen companion diagnostic partnerships, expand representative trial enrollment, and invest in real-world evidence infrastructure. Supply resilience is also critical, particularly for sterile injectables, biologics, antibody-drug conjugates, cell therapies, and radiopharmaceuticals. Regional launch sequencing should reflect regulatory timelines, HTA expectations, local treatment guidelines, diagnostic readiness, and affordability dynamics.

Research Methodology

This executive summary is developed using a structured secondary research approach. Inputs include publicly available data from the International Agency for Research on Cancer, World Health Organization, U.S. FDA, European Medicines Agency, national cancer agencies, peer-reviewed oncology literature, clinical trial registries, and recognized health technology assessment bodies.

The methodology synthesizes epidemiology, regulatory activity, therapeutic innovation, reimbursement trends, regional access patterns, and competitive dynamics across anti-tumor drugs, including chemotherapy, targeted therapy, immuno-oncology, biologics, biosimilars, antibody-drug conjugates, radiopharmaceuticals, and cell-based therapies. Insights are validated through cross-source comparison and are presented as directional industry intelligence rather than patient-level medical guidance or individualized investment advice.

Conclusion

The anti-tumor drugs market is entering a new phase defined by precision medicine, immunotherapy combinations, AI-enabled development, biomarker integration, and intensifying payer scrutiny. Global demand is structurally supported by high cancer incidence, earlier diagnosis, aging populations, expanding clinical research, and broader access to oncology care.

Success will depend on more than scientific novelty. Companies that combine clinically meaningful innovation with reliable manufacturing, diagnostic integration, real-world evidence, and market-specific access strategies will be best positioned to build durable relevance in the global anti-tumor drugs industry.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Anti-Tumor Drugs Market, by Drug Class

  • 7.1. Chemotherapy
  • 7.2. Hormonal Therapy
  • 7.3. Immunotherapy
  • 7.4. Targeted Therapy

8. Anti-Tumor Drugs Market, by Molecule Type

  • 8.1. Monoclonal Antibody
  • 8.2. Nucleic Acid
  • 8.3. Peptide
  • 8.4. Small Molecule

9. Anti-Tumor Drugs Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous
  • 9.4. Topical

10. Anti-Tumor Drugs Market, by Therapy Line

  • 10.1. First-Line Therapy
  • 10.2. Second-Line Therapy

11. Anti-Tumor Drugs Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Anti-Tumor Drugs Market, by Indication

  • 12.1. Breast Cancer
  • 12.2. Colorectal Cancer
  • 12.3. Lung Cancer
  • 12.4. Prostate Cancer

13. Anti-Tumor Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Anti-Tumor Drugs Market, by End User

  • 14.1. Ambulatory Surgical Centers
  • 14.2. Clinics
  • 14.3. Home Care
  • 14.4. Hospitals

15. Anti-Tumor Drugs Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Anti-Tumor Drugs Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Anti-Tumor Drugs Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. AbbVie Inc.
  • 19.2. Amgen Inc.
  • 19.3. AstraZeneca plc
  • 19.4. Aurobindo Pharma Limited
  • 19.5. Bayer AG
  • 19.6. Bristol-Myers Squibb Company
  • 19.7. Cybrexa Therapeutics
  • 19.8. Dr. Reddy's Laboratories Ltd.
  • 19.9. Eisai Co., Ltd.
  • 19.10. Eli Lilly and Company
  • 19.11. F. Hoffmann-La Roche Ltd
  • 19.12. Getwell Oncology
  • 19.13. Johnson & Johnson
  • 19.14. Merck & Co., Inc.
  • 19.15. Novartis AG
  • 19.16. Otsuka Pharmaceutical Co., Ltd
  • 19.17. Pfizer Inc.
  • 19.18. Pharma Mar, S.A.
  • 19.19. Sanofi SA
  • 19.20. Taiho Oncology, Inc
  • 19.21. Takeda Pharmaceutical Company Limited
  • 19.22. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-TUMOR DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANTI-TUMOR DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANTI-TUMOR DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANTI-TUMOR DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-TUMOR DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ANTI-TUMOR DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HORMONAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HORMONAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HORMONAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PEPTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SMALL MOLECULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SMALL MOLECULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SMALL MOLECULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. NATO ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 252. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 256. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 257. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 270. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 273. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. ITALY ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 282. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 283. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 284. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 288. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 291. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 292. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 293. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. INDIA ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 306. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 308. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 309. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 310. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 311. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 312. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 315. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 318. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 319. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 320. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 321. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 322. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 324. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 326. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 327. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 328. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 329. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 330. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 331. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 332. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 333. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 335. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 336. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 337. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 338. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 339. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)